• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑癌基因脆性组氨酸三联体(Fhit)正向调节癌细胞 MHC Ⅰ类分子的表达。

The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.

机构信息

Servicio de Análisis Clínicos & Inmunología, Hospital Universitario Virgen de las Nieves, Granada, Spain.

出版信息

J Pathol. 2012 Jul;227(3):367-79. doi: 10.1002/path.4029. Epub 2012 May 23.

DOI:10.1002/path.4029
PMID:22451343
Abstract

MHC class I (MHC-I) molecules are ubiquitously expressed on the cells of an organism. Study of the regulation of these molecules in normal and disease conditions is important. In tumour cells, the expression of MHC-I molecules is very frequently lost, allowing these cells to evade the immune response. Cancers of different histology have shown total loss of MHC-I molecule expression, due to a coordinated transcriptional down-regulation of various antigen-processing machinery (APM) components and/or MHC-I heavy chains. The mechanisms responsible for these alterations remain unclear. We determined the possible genes involved by comparing MHC-I-positive with MHC-I-negative murine metastases derived from the same fibrosarcoma tumour clone. MHC-I-negative metastases showed transcriptional down-regulation of APM and MHC-I heavy chains. The use of microarrays and subtraction cDNA libraries revealed four candidate genes responsible for this alteration, but two of them were ruled out by real-time RT-PCR analyses. The other two genes, AP-2α and Fhit tumour suppressors, were studied by using siRNA to silence their expression in a MHC-I-positive metastatic cell line. AP-2α inhibition did not modify transcriptional expression of APM components or MHC-I heavy chains or surface expression of MHC-I. In contrast, silencing of the Fhit gene produced the transcriptional down-regulation of APM components and MHC-I heavy chains and decreased MHC-I surface expression. Moreover, transfection of Fhit in MHC-I-negative tumour cell lines restored MHC-I cell surface expression. These data indicate that defects in Fhit expression may promote MHC-I down-regulation in cancer cells and allow escape from immunosurveillance(#).

摘要

MHC I 类分子(MHC-I)在生物体的细胞中广泛表达。研究这些分子在正常和疾病条件下的调节非常重要。在肿瘤细胞中,MHC-I 分子的表达经常丢失,使这些细胞能够逃避免疫反应。不同组织学的癌症已经显示出 MHC-I 分子表达的完全丧失,这是由于各种抗原加工机制(APM)成分和/或 MHC-I 重链的协调转录下调所致。导致这些改变的机制尚不清楚。我们通过比较来自同一纤维肉瘤肿瘤克隆的 MHC-I 阳性和 MHC-I 阴性鼠转移瘤,确定了可能涉及的基因。MHC-I 阴性转移瘤显示 APM 和 MHC-I 重链的转录下调。使用微阵列和消减 cDNA 文库揭示了四个可能导致这种改变的候选基因,但实时 RT-PCR 分析排除了其中两个。另外两个基因,AP-2α 和 Fhit 肿瘤抑制因子,通过使用 siRNA 沉默 MHC-I 阳性转移细胞系中的表达来研究。AP-2α 抑制不会改变 APM 成分或 MHC-I 重链的转录表达或 MHC-I 的表面表达。相比之下,Fhit 基因的沉默导致 APM 成分和 MHC-I 重链的转录下调,并降低 MHC-I 的表面表达。此外,Fhit 转染到 MHC-I 阴性肿瘤细胞系中恢复了 MHC-I 细胞表面表达。这些数据表明,Fhit 表达缺陷可能促进癌细胞中 MHC-I 的下调,并允许其逃避免疫监视(#)。

相似文献

1
The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.抑癌基因脆性组氨酸三联体(Fhit)正向调节癌细胞 MHC Ⅰ类分子的表达。
J Pathol. 2012 Jul;227(3):367-79. doi: 10.1002/path.4029. Epub 2012 May 23.
2
Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.头颈部癌中MHC II类抗原加工途径的干扰素-γ诱导性丧失:转录后及表观遗传调控的证据
Br J Dermatol. 2008 May;158(5):930-40. doi: 10.1111/j.1365-2133.2008.08465.x. Epub 2008 Feb 16.
3
MHC class I down-regulation: tumour escape from immune surveillance? (review).MHC I类分子下调:肿瘤逃避免疫监视?(综述)
Int J Oncol. 2004 Aug;25(2):487-91.
4
Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.FRA16D/WWOX和FRA3B/FHIT基因在血液系统恶性肿瘤中的表达
Mol Cancer Res. 2003 Nov;1(13):940-7.
5
MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells.MHC Ⅰ类分子作为肿瘤抑制基因调节黑色素瘤细胞的细胞周期基因表达、侵袭和内在致瘤性。
Carcinogenesis. 2012 Mar;33(3):687-93. doi: 10.1093/carcin/bgr318. Epub 2012 Jan 4.
6
Fhit regulates invasion of lung tumor cells.脆性组氨酸三联体基因调控肺癌细胞的侵袭。
Oncogene. 2010 Feb 25;29(8):1203-13. doi: 10.1038/onc.2009.418. Epub 2009 Nov 23.
7
Immune selection in murine tumors. Ph.d thesis.小鼠肿瘤中的免疫选择。博士论文。
APMIS Suppl. 2003(106):1-46.
8
Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.HPV16相关肿瘤的免疫逃逸表型:MHC I类分子表达在进展和治疗过程中的变化
Int J Oncol. 2005 Feb;26(2):521-7.
9
MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?小鼠肿瘤中的MHC II类抗原呈递途径:肿瘤对免疫监视的逃避?
Br J Cancer. 2000 Nov;83(9):1192-201. doi: 10.1054/bjoc.2000.1415.
10
Fhit protein inhibits cell growth by attenuating the signaling mediated by nuclear factor-kappaB in colon cancer cell lines.脆性组氨酸三联体(Fhit)蛋白通过减弱核因子-κB介导的信号传导来抑制结肠癌细胞系中的细胞生长。
Exp Cell Res. 2006 Aug 1;312(13):2433-42. doi: 10.1016/j.yexcr.2006.04.004. Epub 2006 Apr 25.

引用本文的文献

1
Implication of Amyloid Precursor-like Protein 2 Expression in Cutaneous Squamous Cell Carcinoma Pathogenesis.淀粉样前体样蛋白 2 表达在皮肤鳞状细胞癌发病机制中的意义。
In Vivo. 2024 Jan-Feb;38(1):399-408. doi: 10.21873/invivo.13452.
2
Transcriptomic FHIT/pHER2 signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer.转录组 FHIT/pHER2 特征作为非小细胞肺癌预后和免疫治疗反应的预测因子。
Front Immunol. 2022 Dec 5;13:1058531. doi: 10.3389/fimmu.2022.1058531. eCollection 2022.
3
Deregulation of HLA-I in cancer and its central importance for immunotherapy.
肿瘤中 HLA-I 的失调及其对免疫治疗的核心重要性。
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002899.
4
Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.超越单纯的肽抗原:基于肽的癌症疫苗的复杂世界。
Front Immunol. 2021 Jun 30;12:696791. doi: 10.3389/fimmu.2021.696791. eCollection 2021.
5
T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy.T 细胞受体模拟抗体在癌症免疫治疗中的应用。
Mol Cancer Ther. 2021 Sep;20(9):1533-1541. doi: 10.1158/1535-7163.MCT-21-0115. Epub 2021 Jun 25.
6
MHC heterogeneity and response of metastases to immunotherapy.主要组织相容性复合体(MHC)异质性与转移瘤对免疫治疗的反应。
Cancer Metastasis Rev. 2021 Jun;40(2):501-517. doi: 10.1007/s10555-021-09964-4. Epub 2021 Apr 15.
7
The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.MHC Class-I Transactivator NLRC5:对癌症免疫学的影响及在癌症免疫治疗中的潜在应用。
Int J Mol Sci. 2021 Feb 17;22(4):1964. doi: 10.3390/ijms22041964.
8
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy.抗原加工与呈递在癌症中的作用及免疫检查点抑制剂免疫疗法的疗效
Cancers (Basel). 2021 Jan 4;13(1):134. doi: 10.3390/cancers13010134.
9
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy.癌症中MHC I类分子下调:潜在机制及癌症免疫治疗的潜在靶点
Cancers (Basel). 2020 Jul 2;12(7):1760. doi: 10.3390/cancers12071760.
10
Restoration of MHC-I on Tumor Cells by Fhit Transfection Promotes Immune Rejection and Acts as an Individualized Immunotherapeutic Vaccine.通过Fhit转染恢复肿瘤细胞上的MHC-I可促进免疫排斥并作为个体化免疫治疗疫苗。
Cancers (Basel). 2020 Jun 12;12(6):1563. doi: 10.3390/cancers12061563.